z-logo
Premium
Feasibility, efficacy, safety, and acceptability of mifepristone–misoprostol for medical abortion in the Democratic People's Republic of Korea
Author(s) -
Tran Nguyen Toan,
Jang Myong Chon,
Choe Yong Su,
Ko Won Suk,
Pyo Hae Suk,
Kim Ok Suk
Publication year - 2010
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2010.01.012
Subject(s) - medicine , misoprostol , abortion , medical abortion , mifepristone , obstetrics , rural area , abortion law , pregnancy , unsafe abortion , family planning , gynecology , family medicine , demography , environmental health , population , research methodology , genetics , pathology , biology , sociology
Objective To examine the feasibility, efficacy, safety, and acceptability of medical abortion among rural and urban women up to 56 days of pregnancy in the Democratic People's Republic of Korea. Method A total of 199 women (rural n = 95, urban n = 104) recruited from 2 rural and 2 urban reproductive health clinics received 200 mg of oral mifepristone followed 2 days later by 400 μg of sublingual misoprostol. The women's abortion status and satisfaction level were determined 2 weeks later. Results Overall complete abortion occurred in 96.0% of the women; there was no statistically significant difference between the groups (rural 95.8%, 95% confidence interval [CI], 89.6–98.8; urban 96.2%, 95% CI, 90.4–98.9). The 2 groups reported similar adverse effects. In total, 90.5% of rural and 88.5% of urban participants were satisfied or very satisfied with the method. Conclusion The high efficacy and acceptability of medical abortion among rural and urban women suggest that medical abortion is a safe alternative to surgical abortion and can be scaled up to other reproductive health clinics in both rural and urban areas of the Democratic People's Republic of Korea, provided that there is appropriate training and supervision.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here